Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
09
06
2023
accepted:
21
11
2023
revised:
02
11
2023
medline:
13
12
2023
pubmed:
13
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
Methylphenidate (MP) is commonly prescribed to treat attention-deficit hyperactivity disorder (ADHD). MP is also taken for non-medical purposes as a recreational drug or "cognitive enhancer". Combined exposure to MP and selective serotonin reuptake inhibitors such as fluoxetine (FLX) can also occur, such as in the treatment of ADHD with depression comorbidity or when patients taking FLX use MP for non-medical purposes. It is unclear if such exposure could subsequently increase the risk for relapse in former cocaine users. We investigated if an acute challenge with MP, FLX, or the combination of MP + FLX could trigger reinstatement of cocaine seeking behavior in a model for relapse in rats. Juvenile rats self-administered cocaine (600 µg/kg/infusion, 1-2 h/day, 7-8 days) and then underwent extinction and withdrawal during late adolescence-early adulthood. Reinstatement was tested at a low dose of MP (2 mg/kg, I.P., comparable to doses used therapeutically) or a high dose of MP (5 mg/kg, comparable to doses used recreationally or as a cognitive enhancer), with or without FLX (2.5-5 mg/kg, I.P.). An acute challenge with the high dose of MP (5 mg/kg), with or without FLX, reinstated cocaine seeking behavior to levels comparable to those seen after an acute challenge with cocaine (15 mg/kg, I.P.). The low dose of MP (2 mg/kg) with or without FLX did not reinstate cocaine seeking behavior. Our results suggest that acute exposure to a high dose of MP, with or without FLX, may increase the risk for relapse in individuals who used cocaine during the juvenile period.
Identifiants
pubmed: 38086900
doi: 10.1038/s41386-023-01777-z
pii: 10.1038/s41386-023-01777-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : R21 DA031916
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046794
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF. A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:593–9.
pubmed: 17270333
pmcid: 1907363
doi: 10.1016/j.pnpbp.2006.12.004
Cami J, Farre M. Drug addiction. N Engl J Med. 2003;349:975–86.
pubmed: 12954747
doi: 10.1056/NEJMra023160
Kapur A. Is methylphenidate beneficial and safe in pharmacological cognitive enhancement? CNS Drugs. 2020;34:1045–62.
pubmed: 32794136
doi: 10.1007/s40263-020-00758-w
Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68:611–27.
pubmed: 11325419
doi: 10.1016/S0091-3057(01)00464-6
Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1996;35:978–87.
pubmed: 8755794
doi: 10.1097/00004583-199608000-00008
Parran TV Jr., Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med. 1991;151:781–3.
pubmed: 1849397
doi: 10.1001/archinte.1991.00400040119027
Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002;14:219–23.
pubmed: 11981294
doi: 10.1097/00008480-200204000-00013
Clemow DB. Misuse of methylphenidate. Curr Top Behav Neurosci. 2017;34:99–124.
pubmed: 26695166
doi: 10.1007/7854_2015_426
McCabe SE, Veliz P, Boyd CJ. Early exposure to stimulant medications and substance-related problems: the role of medical and nonmedical contexts. Drug Alcohol Depend. 2016;163:55–63.
pubmed: 27129621
pmcid: 4921894
doi: 10.1016/j.drugalcdep.2016.03.019
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26:1501–10.
pubmed: 16999660
pmcid: 1794223
doi: 10.1592/phco.26.10.1501
White BP, Becker-Blease KA, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health. 2006;54:261–8.
pubmed: 16539218
doi: 10.3200/JACH.54.5.261-268
Drug abuse statistics. Retrieved October 9, 2023 from: https://drugabusestatistics.org/ .
Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH. Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. J Am Acad Child Psychitary. 2020;59:100–12.
doi: 10.1016/j.jaac.2019.06.012
Ponnet K, Tholen R, De Bruyn S, Wouters E, Van Ouytsel J, Walrave M, et al. Students’ stimulant use for cognitive enhancement: a deliberate choice rather than an emotional response to a given situation. Drug Alcohol Depend. 2021;218:108410.
pubmed: 33250387
doi: 10.1016/j.drugalcdep.2020.108410
Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol. 1997;17:485–8.
pubmed: 9408812
doi: 10.1097/00004714-199712000-00008
Vogel M, Bucher P, Strasser J, Liechti ME, Krahenbuhl S, Dursteler KM. Similar and different? Subjective effects of methylphenidate and cocaine in opioid-maintained patients. J Psychoactive Drugs. 2016;48:93–100.
pubmed: 26940988
doi: 10.1080/02791072.2015.1130883
Dursteler KM, Berger EM, Strasser J, Caflisch C, Mutschler J, Herdener M, et al. Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Subst Abuse Rehabil. 2015;6:61–74.
pubmed: 26124696
pmcid: 4476488
doi: 10.2147/SAR.S50807
Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:CD007380.
pubmed: 27670244
Castells X, Casas M, Perez-Mana C, Roncero C, Vidal X, Capella D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010;2:CD007380.
Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry. 1998;59:300–5.
pubmed: 9671342
doi: 10.4088/JCP.v59n0605
Elangovan N, Barbato M, Cooper T, Winsberg B. Neurohormonal and behavioral response to methylphenidate in cocaine abstinence. Psychiatry Res. 1996;65:65–71.
pubmed: 9122287
doi: 10.1016/S0165-1781(96)02847-8
Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10:111.
pubmed: 18596945
pmcid: 2438483
Sepulveda DR, Thomas LM, McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract. 2011;24:551–60.
pubmed: 22095577
pmcid: 3277944
doi: 10.1177/0897190011426558
Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 1993;3:1–10.
pubmed: 19630593
doi: 10.1089/cap.1993.3.1
Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med. 2001;155:560–5.
pubmed: 11343498
doi: 10.1001/archpedi.155.5.560
Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438–49.
pubmed: 12611822
doi: 10.1176/appi.ajp.160.3.438
Kadison R. Getting an edge-use of stimulants and antidepressants in college. N Engl J Med. 2005;353:1089–91.
pubmed: 16162878
doi: 10.1056/NEJMp058047
Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord. 2008;12:115–25.
pubmed: 18192623
doi: 10.1177/1087054707311654
Swanson JM, Volkow ND. Increasing use of stimulants warns of potential abuse. Nature. 2008;453:586.
pubmed: 18509418
pmcid: 2681078
doi: 10.1038/453586a
Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Psy. 2008;47:21–31.
doi: 10.1097/chi.0b013e31815a56f1
van Waes V, Steiner H. Fluoxetine and other SSRI antidepressants potentiate addiction-related gene regulation by psychostimulant medications. In: Pinna G, editor Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects. Hauppauge, NY: Nova Science Publishers; 2015. p. 207-25.
Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68:2032–7.
pubmed: 9109529
doi: 10.1046/j.1471-4159.1997.68052032.x
Kuczenski R, Segal DS. Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate. Psychopharmacology. 1999;147:96–103.
pubmed: 10591874
doi: 10.1007/s002130051147
Guan XM, McBride WJ. Fluoxetine increases the extracellular levels of serotonin in the nucleus accumbens. Brain Res Bull. 1988;21:43–46.
pubmed: 2464422
doi: 10.1016/0361-9230(88)90118-9
Wong WC, Ford KA, Pagels NE, McCutcheon JE, Marinelli M. Adolescents are more vulnerable to cocaine addiction: behavioral and electrophysiological evidence. J Neurosci. 2013;33:4913–22.
pubmed: 23486962
pmcid: 3630505
doi: 10.1523/JNEUROSCI.1371-12.2013
Kandel DB, Logan JA. Patterns of drug use from adolescence to young adulthood: I. Periods of risk for initiation, continued use, and discontinuation. Am J Public Health. 1984;74:660–6.
pubmed: 6611092
pmcid: 1651682
doi: 10.2105/AJPH.74.7.660
Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26:479–88.
pubmed: 11927172
doi: 10.1016/S0893-133X(01)00367-0
Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry. 2005;57:1391–6.
pubmed: 15950013
doi: 10.1016/j.biopsych.2004.12.036
Al-Ramadhan FR, Abulmeaty MMA, Alquraishi M, Razak S, Alhussain MH. Effect of Vitamin D3 on depressive behaviors of rats exposed to chronic unpredictable mild stress. Biomedicines. 2023;11:2112.
pubmed: 37626608
pmcid: 10452126
doi: 10.3390/biomedicines11082112
Steiner H, Van Waes V, Marinelli M. Fluoxetine potentiates methylphenidate-induced gene regulation in addiction-related brain regions: concerns for use of cognitive enhancers? Biol Psychiatry. 2010;67:592–4.
pubmed: 19931852
doi: 10.1016/j.biopsych.2009.10.004
Fuchs RA, Tran-Nguyen LT, Specio SE, Groff RS, Neisewander JL. Predictive validity of the extinction/reinstatement model of drug craving. Psychopharmacology. 1998;135:151–60.
pubmed: 9497020
doi: 10.1007/s002130050496
Conrad KL, McCutcheon JE, Cotterly LM, Ford KA, Beales M, Marinelli M. Persistent increases in cocaine-seeking behavior after acute exposure to cold swim stress. Biol Psychiatry. 2010;68:303–5.
pubmed: 20494337
pmcid: 2907460
doi: 10.1016/j.biopsych.2010.03.030
Renoux C, Shin JY, Dell’Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. Br J Clin Pharmacol. 2016;82:858–68.
pubmed: 27145886
pmcid: 5338115
doi: 10.1111/bcp.13000
Manza P, Shokri-Kojori E, Wiers CE, Kroll D, Feldman D, McPherson K, et al. Sex differences in methylphenidate-induced dopamine increases in ventral striatum. Mol Psychiatry. 2022;27:939–46.
pubmed: 34707237
doi: 10.1038/s41380-021-01294-9
Beverley JA, Piekarski C, Van Waes V, Steiner H. Potentiated gene regulation by methylphenidate plus fluoxetine treatment: long-term gene blunting (Zif268, Homer1a) and behavioral correlates. Basal Ganglia. 2014;4:109–16.
pubmed: 25530939
pmcid: 4267118
doi: 10.1016/j.baga.2014.10.001
Van Waes V, Vandrevala M, Beverley J, Steiner H. Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a. Addict Biol. 2014;19:986–95.
pubmed: 23763573
doi: 10.1111/adb.12067
Van Waes V, Beverley J, Marinelli M, Steiner H. Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur J Neurosci. 2010;32:435–47.
pubmed: 20704593
pmcid: 2921647
doi: 10.1111/j.1460-9568.2010.07294.x
Schenk S, Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology. 1999;147:285–90.
pubmed: 10639687
doi: 10.1007/s002130051169
Economidou D, Dalley JW, Everitt BJ. Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking. Biol Psychiatry. 2011;69:266–74.
pubmed: 21109233
doi: 10.1016/j.biopsych.2010.09.040
Borycz J, Zapata A, Quiroz C, Volkow ND, Ferre S. 5-HT 1B receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. Neuropsychopharmacology. 2008;33:619–26.
pubmed: 17487226
doi: 10.1038/sj.npp.1301445
Lamoureux L, Beverley JA, Marinelli M, Steiner H. Fluoxetine potentiates methylphenidate-induced behavioral responses: enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. Addic Neuroscience. 2023;9:100131.
doi: 10.1016/j.addicn.2023.100131
Senior D, McCarthy M, Ahmed R, Klein S, Lee WX, Hadjiargyrou M, et al. Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration. Addic Neuroscience. 2023;8:100127.
doi: 10.1016/j.addicn.2023.100127
Thanos PK, McCarthy M, Senior D, Watts S, Connor C, Hammond N, et al. Combined chronic oral methylphenidate and fluoxetine treatment during adolescence: effects on behavior. Curr Pharm Biotechnol. 2023;24:1307–14.
pubmed: 36306463
doi: 10.2174/1389201024666221028092342
Senior D, Ahmed R, Arnavut E, Carvalho A, Lee WX, Blum K, et al. Behavioral, neurochemical and developmental effects of chronic oral methylphenidate: a review. J Person Med. 2023;13:574.
doi: 10.3390/jpm13040574
Stoops WW, Rush CR. Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des. 2013;19:7026–35.
pubmed: 23574440
pmcid: 3740019
doi: 10.2174/138161281940131209142843
Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry. 2013;70:857–68.
pubmed: 23803700
pmcid: 4358734
doi: 10.1001/jamapsychiatry.2013.1129
Roache JD, Grabowski J, Schmitz JM, Creson DL, Rhoades HM. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol. 2000;20:61–68.
pubmed: 10653210
doi: 10.1097/00004714-200002000-00011
Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10:286–94.
pubmed: 12233989
doi: 10.1037/1064-1297.10.3.286
Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology. 2020;237:2233–55.
pubmed: 32601988
doi: 10.1007/s00213-020-05563-3
Schmidt HD, Pierce RC. Systemic administration of a dopamine, but not a serotonin or norepinephrine, transporter inhibitor reinstates cocaine seeking in the rat. Behav Brain Res. 2006;175:189–94.
pubmed: 16978714
doi: 10.1016/j.bbr.2006.08.009
Sofuoglu M, Sewell RA. Norepinephrine and stimulant addiction. Addic Biol. 2009;14:119–29.
doi: 10.1111/j.1369-1600.2008.00138.x